Prescription Drug News and Research RSS Feed - Prescription Drug News and Research

Canopus BioPharma study confirms efficacy of CB008 drug for Ebola Virus inhibition

Canopus BioPharma study confirms efficacy of CB008 drug for Ebola Virus inhibition

Canopus BioPharma Inc. today announces that it has completed crucial research in confirming efficacy of a prescription drug: CB008 for Ebola Virus inhibition. [More]
National survey shows decrease in alcohol, cigarette and illicit drug use among U.S. teens

National survey shows decrease in alcohol, cigarette and illicit drug use among U.S. teens

A national survey of students in U.S. middle schools and high schools shows some important improvements in levels of substance use. [More]
Doctors prescribe fewer opioids for pain as prescription drug abuse rises

Doctors prescribe fewer opioids for pain as prescription drug abuse rises

Nine in 10 primary care physicians say that prescription drug abuse is a moderate or big problem in their communities and nearly half say they are less likely to prescribe opioids to treat pain compared to a year ago, new Johns Hopkins Bloomberg School of Public Health research suggests. [More]
University of Utah professor develops MORE intervention program for chronic pain patients

University of Utah professor develops MORE intervention program for chronic pain patients

How can people who are dependent on prescription opioids reduce their cravings? Learn to enjoy other aspects of their lives. [More]
New MHA report calls on the country to address mental health issues

New MHA report calls on the country to address mental health issues

Our country is failing those in need of mental health services, according to a new report released by Mental Health America, the nation's leading community-based mental health advocacy organization. MHA for the first time has provided overall rankings for all 50 states and the District of Columbia on mental health status and access, and calls on the country to address mental health before Stage 4. [More]
Young adults who skip college are at higher risk for nonmedical prescription opioid use

Young adults who skip college are at higher risk for nonmedical prescription opioid use

A study just released by Columbia University's Mailman School of Public Health compared the use of prescription opioids and stimulants among high school graduates, non-graduates, and their college-attending peers, and found that young adults who do not attend college are at particularly high risk for nonmedical prescription opioid use and disorder. [More]
BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

BerGenBio AS, an oncology biopharmaceutical company, today announces that the US Food and Drug Administration has granted orphan-drug designation for BGB324 for treatment of acute myeloid leukaemia (AML). [More]
Prescription opioids involved in 67.8% of nationwide ED visits in 2010, find researchers

Prescription opioids involved in 67.8% of nationwide ED visits in 2010, find researchers

Researchers from Rhode Island and The Miriam hospitals and the Stanford University School of Medicine have found that prescription opioids, including methadone, were involved in 67.8 percent of (or over 135,971 visits to) nationwide emergency department (ED) visits in 2010, with the highest proportion of opioid overdoses occurring in the South. [More]
FDA accepts Amgen's evolocumab BLA for review

FDA accepts Amgen's evolocumab BLA for review

Amgen today announced that the U.S. Food and Drug Administration has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol. [More]
Impax announces submission of EMA Marketing Authorization Application for IPX066

Impax announces submission of EMA Marketing Authorization Application for IPX066

Impax Laboratories (Netherlands) B.V., a wholly owned subsidiary of Impax Laboratories, Inc. today announced that it has submitted a Marketing Authorization Application for IPX066 to the European Medicines Agency. IPX066 is an investigational extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson's disease. [More]
Eight million US women skip cervical cancer screening in the past five years

Eight million US women skip cervical cancer screening in the past five years

Despite evidence that cervical cancer screening saves lives, about eight million women ages 21 to 65 years have not been screened for cervical cancer in the past five years, according to a new Vital Signs report from the Centers for Disease Control and Prevention. More than half of new cervical cancer cases occur among women who have never or rarely been screened. [More]
Avanir Pharmaceuticals to publish AVP-825 phase III study results in the journal 'Headache'

Avanir Pharmaceuticals to publish AVP-825 phase III study results in the journal 'Headache'

Avanir Pharmaceuticals, Inc. today announced the publication of results from TARGET, a pivotal phase III study evaluating the efficacy and safety of AVP-825 22mg in the January 2015 issue of Headache (Early access is now available). [More]
Penn Medicine-developed drug gets FDA orphan status for PNH treatment

Penn Medicine-developed drug gets FDA orphan status for PNH treatment

A Penn Medicine-developed drug has received orphan status from the Food and Drug Administration (FDA) this month for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening disease that causes anemia due to destruction of red blood cells and thrombosis. [More]
Viewpoints: Fund CHIP; media overdrive on Ebola; slowdown in Medicare costs

Viewpoints: Fund CHIP; media overdrive on Ebola; slowdown in Medicare costs

In what may be a hopelessly quixotic effort, supporters of the federal Children's Health Insurance Program are trying to persuade Congress to renew its funding almost a year in advance -; and in a lame-duck session. Nevertheless, lawmakers ought to heed that call. The program plugs a troubling gap between Medicaid and the Affordable Care Act's subsidized plans, and states need to know whether they can count on federal funding or whether they will have to spend far more dollars of their own (10/21). [More]
Loyola University Health System to hold medication take-back day

Loyola University Health System to hold medication take-back day

Loyola University Health System will partner with the Cook County Sheriff's Department to hold a medication take-back day. [More]
NIH announces 11 awards to improve public health outcomes related to substance use, addiction

NIH announces 11 awards to improve public health outcomes related to substance use, addiction

More than $11 million over three years will be used to support research exploring the use of social media to advance the scientific understanding, prevention, and treatment of substance use and addiction. [More]
Genome Canada awards $6M grant to CAMH and Assurex Health

Genome Canada awards $6M grant to CAMH and Assurex Health

Assurex Health and Canada's Centre for Addiction and Mental Health (CAMH) today announced they have received a $6 million grant from Genome Canada, an agency of the Canadian government, to study the benefits of genetic testing to guide medication decisions for patients with depression or schizophrenia. [More]
Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%. [More]
Medicare Advantage plans marked by shortcomings

Medicare Advantage plans marked by shortcomings

The New York Times reports that these problem areas include rejection of claims for medical services and limits on prescription drug coverage. News outlets also report on ACOs grades and Medicare Advantage rate shifts. [More]
Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Astellas reported today that isavuconazole demonstrated successful outcomes in the treatment of mucormycosis according to data from the phase 3 isavuconazole VITAL study being presented at IDWeek on October 10, 2014, in Philadelphia, Pa. [More]